Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials.

Abstract

OBJECTIVE:

The aim of this study was to assess the efficacy of different dosage regimens of tanezumab among individuals living with chronic low back pain (CLBP).

METHODS:

PubMed, Embase, The Cochrane Library, and other databases were searched from inception until August 2021. Randomized controlled trials investigating the efficacy and safety of tanezumab in individuals with CLBP were included. Data were extracted independently by 2 investigators and assessed the study quality by the Cochrane risk-of-bias tool. The measurements include low back pain intensity and Roland-Morris Disability Questionnaire. The incidence of adverse events and serious adverse events was set to assess the safety of tanezumab for CLBP.

RESULTS AND DISCUSSION:

Three high-quality randomized controlled trials with 3414 patients were finally included in our analysis. Tanezumab, respectively, led to a notable decrease compared with placebo in low back pain intensity (mean difference, -0.62; 95% confidence interval [CI], -0.77 to -0.46; P < 0.01) and Roland-Morris Disability Questionnaire (mean difference, -0.64; 95% CI, -0.80 to -0.47; P = 0.01). In addition, no significant difference existed between tanezumab and placebo groups (risk ratio, 1.10; 95% CI, 0.81-1.49; P = 0.55) in the adverse events and (risk ratio, 1.06; 95% CI, 0.34-3.27; P = 0.93) serious adverse events.

CONCLUSIONS:

Intravenous and subcutaneous tanezumab injections as treatment for improving CLBP have promising clinical application as its great improvement on all efficacy and its controllable safety issues. Furthermore, intravenous and subcutaneous tanezumab injections were proved to achieve excellent and long-term curative effect on CLBP through our subgroup analysis and comparison.

• Authors: Jinrong Lian, Jiahe Wang, Xiang Li, Siyuan Yang, Hang Li, Yi Zhong, Heng Gao, Gang Chen
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2023 Jan-Feb 01 Vol. 46 Issue 1 Pg. 6-16 ISSN: 1537-162X [Electronic] United States
• PMID: 36542785 (Publication Type: Journal Article, Meta-Analysis)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• tanezumab

Topics

• Humans
• Administration, Intravenous
• Antibodies, Monoclonal, Humanized (therapeutic use, adverse effects)
• Chronic Pain (drug therapy)
• Low Back Pain (drug therapy, chemically induced)
• Randomized Controlled Trials as Topic